bio shares dated 26/8/11, page-9

Hi dooley

I completely understand your hesitation re msb given its market cap and no phase 3 trial completed yet. I'm sure you're not alone and many investors are watching msb and will feel more comfortable getting on board if/when a phase 3 is complete and they have a product on the market. If or when this happens the flood gates will open and their entire pipeline will have more credibility, and the patience of current shareholders will pay off big time.

And it's my understanding that single-blind trials are particularly risky in social science and psychology research, when the experimenter may consciously or subconsciously influence the behaviour of the subject. I fail to see how this would impact on the results of medical trials though.